Using a binary adenoviral system, we recently showed that the human telomerase reverse transcriptase (hTERT) promoter induces tumor-specific Bax gene expression. However, the strong cytotoxicity of Bax and other pro-apoptotic genes to packaging 293 cells has so far hindered construction of the desired single adenoviral vectors expressing toxic genes. We report here the construction of a single bicistronic adenoviral vector for tumor-specific Bax expression. The vector (Ad/gBax) utilizes the Tet-Off system and expresses a GFP/Bax fusion protein for easy detection. The hTERT promoter drives the expression of tTA, a transactivator capable of binding to TRE (tetracycline-responsive element) in the absence of tetracycline, which in turn induces expression of the GFP-Bax gene. The addition of tetracycline in 293 cells blocks the binding of tTA to TRE and substantially inhibits GFP -Bax expression and toxicity, thus allowing the packaging and production of Ad/gBax. Our data show that Ad/gBax could drive the high expression of GFP -Bax in tumor cells but not in normal cells and mouse tissues. Furthermore, the expression of GFP -Bax fusion protein elicited tumorspecific apoptosis in a variety of human cancer cells in vitro and in vivo at a level comparable to that induced by the binary system. Thus, Ad/gBax may become a potent therapeutic agent for the treatment of cancers.
Introduction
Cancer gene therapies using pro-apoptotic genes to force cancer cells through the apoptotic pathway have been tested extensively pre-clinically and clinically. These genes include p53 (Roth et al., 1996) , TRAIL , Bak (Pataer et al., 2000) , Bax and various caspase genes (Shariat et al., 2001; Nishimura et al., 2001) . While p53 gene therapy showed promise clinically in the treatment of cancers, and is relatively safe in terms of its effects on normal cells, other genes may be needed when tumors are resistant to p53. Bak and Bax are examples of genes that can kill both p53-sensitive and p53-resistant cancer cells both in vitro and in vivo (Pataer et al., 2000; Kawaga et al., 2000) . However, most of these pro-apoptotic genes, although very cytotoxic, are still limited to laboratory research and have not yet been tested clinically. One of the reasons for this is their toxic effects on normal cells, since these pro-apoptotic genes are not selective but can kill both cancer cells and normal cells.
To prevent the killing of normal cells, the genes must be targeted to the tumor. Tissue-or cell-specific promoters represent one of the main methods of gene targeting. Several promoters have been identified and exploited to target transgene expression in tumors (Vile and Hart, 1993; Osaki et al., 1994; Chen et al., 1995; Parr et al., 1997) . However, most of these promoters are much weaker than commonly used viral promoters, such as the cytomegalovirus (CMV) early promoter and SV40 early promoter. In addition, most of these promoters are limited to certain types of tumor and cannot be used broadly in tumors of different origins because of the marked heterogeneity of the tumors. The search for a universal tumor-specific promoter has eluted researchers for a long time.
We and others recently demonstrated that the human telomerase reverse transcriptase (hTERT) promoter is useful for targeted transgene expression in human cancer cells Koga et al., 2000) . hTERT, which is the catalytic subunit of human telomerase, is highly active in immortalized cell lines and over 85% of human cancers, but inactive in most somatic cells (Kim et al., 1994; Shay and Bacchetti, 1997) . As the first study of the feasibility of using the hTERT promoter in adenovirus-mediated cancer gene therapy, we used a binary adenovirus system to show that the hTERT promoter drove strong tumor-specific Bax gene expression and induced tumor-specific apoptosis . However, although the binary system overcame the problem with the toxic effects of proapoptotic genes on packaging 293 cells, the absolute need for the co-delivery of two separate vectors made the clinical use of this strategy difficult if not unfeasible. Regardless, because hTERT is highly active in 293 cells, constructing a straightforward single adenoviral vector expressing the Bax gene directly from the hTERT promoter is extremely difficult, if not impossible. We were unable to obtain such a vector despite tenacious efforts. There have neither been any reports so far on the construction of single adenoviral vectors for the expression of Bax or other strong proapoptotic genes using hTERT promoter. Here we report that the Tet-Off system can be used to solve this problem. A single bicistronic adenoviral vector expressing the GFP/Bax fusion gene from the hTERT promoter (Ad/hTERT -gBax or Ad/gBax) was constructed using the Tet-Off system and evaluated in vitro and in vivo. We further showed that Ad/gBax induced tumor-specific GFP-Bax expression, which in turn elicited tumor-specific apoptosis in vitro, suppressed tumor growth in nude mice, and prevented the toxicity of the Bax gene in vitro and in vivo.
Results

Construction of Ad/gBax
The high activity of the hTERT promoter in 293 cells and the strong pro-apoptotic activity of Bax protein led us to design and construct a bicistronic adenoviral vector, Ad/hTERT -gBax. This bicistronic vector as modified combined the two expression cassettes of the Tet-Off system (BD Clontech, San Francisco, CA, USA) into a single vector (Figure 1a) . One expression cassette consisted of a transactivator, tTA, which is a fusion of the tetracycline repressor (TetR) to the VP16 activation domain and is driven by the hTERT promoter. The second cassette contained the cDNA of the GFP/Bax fusion protein under the control of a compound promoter consisting of TRE and the minimal immediate early promoter of CMV. GFP was included to facilitate the selection of recombinant virus and the detection of expression products. In the absence of Tc, hTERT would drive the expression of tTA protein, which would then turn on the expression of GFP -Bax. However, when Tc is added, for instance, in 293 cells, it will bind to the tTA protein and inhibit the binding of tTA to TRE, thus inhibiting the expression of GFP-Bax and protecting the 293 cells from Bax-induced apoptosis, hence allowing virus particle packaging and propagation. Using the above strategy, we successfully constructed Ad/gBax and the titers of Ad/gBax produced in the presence of tetracycline were in line with those of control, nontoxic vectors (data not shown). Figure 1b shows the GFPBax expression induced by Ad/gBax after a 24-h infection in H1299 lung cancer cells, and the repressibility of gene expression by Tc. As little of 1 ng/ml Tc started to inhibit GFP-Bax expression; 5 ng/ml significantly reduced the GFP-Bax level; and by 1 mg/ ml, GFP-Bax was expressed at a level close to endogenous Bax protein (data not shown). Further increases in the Tc concentration, however, did not inhibit GFP-Bax anymore (data not shown), suggesting the bottom-line leakage of the Tet-Off system. Ad/gBax drives tumor-specific GFP/Bax expression in human cancer cells
To test whether Ad/gBax can drive tumor-specific GFP-Bax gene expression and induce apoptosis, we used several human cancer cell lines from varying origins and compared the expression of GFP -Bax from Ad/hTERT -gBax with the expression of GFP from Ad/CMV -GFP. These cancer cell lines include: four lung cancers with various p53 statuses, H1299 (null), H358 (null), H322 (mut), and A549 (wt); HepG2 (liver); Lovo (colon); Siha (cervix); OVCAR3 (ovary); DU145 (prostate); HTB9 (bladder) and Saos-2 (bone). NHFB cells were used as a control. As shown in Figure 2 , at 48 h after virus infection, Ad/ CMV -GFP drove very strong GFP expression in all tumor and normal cells, while Ad/gBax only induced a high level of GFP -Bax in cancer cells. There was no detectable GFP -Bax in the NHFB cells. More importantly, many of the cells of cancer cell lines underwent apoptosis, suggesting that the fusion . hTERT promoter drives the expression of a transactivator fusion protein (tTA, tetracycline repressor protein and the activation domain of VP16). GFP -Bax (gBax) fusion protein is under the control of a synthetic minimal promoter composed of TRE and CMV mini-promoter, which is silent unless activated by tTA. In the absence of Tc, tTA binds to TRE and triggers the expression of GFP-Bax. When Tc is added to the medium, tTA is bound by Tc and unable to bind to TRE and activate the expression of GFP -Bax. (b) Ad/hTERT -gBax induces GFP -Bax expression in H1299 cells and the expression is repressed by Tc in a dose-dependent manner. Western blot was performed 24 h after Ad/hTERT -gBax infection using an anti-Bax antibody (N-20, Santa Cruz Biotechnology, CA, USA). The corresponding apoptosis population after 72 h as determined by FACS analysis is listed under each lane protein GFP -Bax has similarly strong pro-apoptotic activity to that of the intact Bax protein. These cancer and normal cells have varying endogenous Bax protein expression (data not shown), which apparently is not a factor in determining the apoptotic effect of Ad/gBax. It is noteworthy that Ad/gBax induced weak GFP -Bax expression in some Saos-2 cells, which reportedly use an alternative lengthening of telomeres (ALT) pathway to maintain telomere length rather than using telomerase (Bryan et al., 1997) . A small percentage of Saos-2 cells also underwent apoptosis (Figure 2 ). Komata et al (2001) recently showed that their hTERT/rev -caspase-6 construct could not kill two immortalized ALT pathway fibroblast cell lines. In comparison, osteosarcoma Saos-2 cells apparently have heterogeneous population of both ALT pathway cells and telomerase pathway cells. Indeed, when we infected Saos-2 cells with a reporter construct, Ad/ hTERT -LacZ, and stained for b-gal-positive cells, about 25% of cells have week hTERT promoter activity (data not shown).
Ad/gBax induces apoptosis in human cancer cell in vitro
To further investigate the apoptosis-inducing effect of Ad/gBax as suggested by the above fluorescent microscopy observations, we performed two additional experiments. In the first experiment, cell viability was determined by an XTT assay at 24, 48 and 72 h after infection with Ad/gBax. Ad/CMV -GFP was used as a negative control, and Ad/GT -Bax+Ad/hTERT -GV16, our previously characterized binary system used Figure 2 Tumor-specific expression of GFP -Bax by Ad/hTERT -gBax in human cancer cells. Cells were treated with the same dosage of Ad/CMV -GFP and Ad/gBax as described in Materials and methods. After 48 h, the expression of GFP -Bax was monitored using a fluorescence microscope and shown on the left panel; cell morphology was monitored with a Nikon digital camera and shown on the right panel to induce Bax expression, was used as a positive control. PBS was used as a mock infection. As shown in Figure 3a , both Ad/gBax and Ad/GT -Bax+Ad/ hTERT -GV16 resulted in comparable cell killing in all cancer cells, including cells of the four lungs cancer cell lines, and HepG2 liver cancer cells. In the NHFB cells, neither treatment had an obvious effect on cell growth because of the low hTERT promoter activity in normal cells. It should be pointed out, however, that normal cells are susceptible to Bax-induced apoptosis, since the use of a constitutively active promoter PGK to drive Bax expression in NHFB cells or normal human bronchial epithelial cells can kill these cells ; also see Figure 3a , NHFB panel, dashed line). Ad/CMV -GFP had no obvious effect on any of these cell lines. In the second experiment, we used fluorescence-activated cell sorter (FACS) analysis to confirm that the growth suppression caused by GFPBax was due to apoptosis rather than to growth inhibition. All the cancer cells and NHFB cells were treated with Ad/gBax and binary vectors. Cells were harvested 72 h later and subjected to FACS analysis to determine the fraction of apoptotic cells, which was done by quantifying the sub-G1 population ( Figure  3b ). Ad/gBax and Ad/GT -Bax+Ad/hTERT -GV16 produced comparable apoptosis populations in cancer Ad/gBax induces tumor-specific GFP-Bax gene expression in vivo and suppresses xenograft tumor growth
To further evaluate the feasibility of using Ad/gBax for in vivo Bax gene therapy, we established H1299 tumors subcutaneously in nude mice and treated the tumors with Ad/gBax. Again, Ad/CMV -GFP was used as a negative control, Ad/GT-Bax+Ad/hTERT -GV16 as a positive control, and PBS as a mock infection. After three sequential intratumoral injections of the vectors, tumor size was monitored for 4 weeks. When tumors reached 15 mm in diameter, the mice had to be sacrificed according to our institutional policy. Ad/ gBax and Ad/GT -Bax+Ad/hTERT-GV16 produced the same level of tumor growth suppression, and this differed significantly from the results in tumors treated with PBS or Ad/CMV -GFP (Figure 4a , P50.01). It is noteworthy that tumors in Ad/gBax and Ad/GTBax+Ad/hTERT -GV16 treatment groups started to grow again after about 30 days. We have previously showed that regrowing tumors after intralesional administration of adenovectors were susceptible to a second round of such treatment (b) GFP -Bax gene expression and apoptosis shown by fluorescence microscopy, Bax immunostaining, and TUNEL. Liver samples were collected 2 days after systemic injection of viral vectors; tumor samples were collected 2 days after the first intratumor injection of binary vectors. Frozen sections were used for GFP detection; formalin-fixed, paraffin-embedded sections were used for Bax immunostaining and TUNEL gBax can produce GFP -Bax and induce apoptosis in tumors and but not in normal tissue in vivo.
Discussion
The Bax gene is one of the best-characterized and most potent proapoptotic genes. We and others Tai et al., 1999; Xiang et al., 2000; Andriani et al., 2001 ) have tried to exploit the strong cytotoxicity of the Bax protein for potential cancer gene therapy using adenovirus-mediated gene transfer. However, the promiscuous cell killing by Bax gene products has complicated the construction of adenoviral vectors. Two inducible binary systems were designed to circumvent the toxicity to packaging 293 cells: the Gal4 -VP16 system and the LoxP -Cre system (Xiang et al., 2000) , but both caused the non-selective overexpression of Bax which led to apoptosis in a wide variety of cells: tumor, normal, p53 wild-type, null and mutants of various origins. This indiscriminate cytotoxicity of Bax protein called for tumor-targeting. However, initial efforts were largely successful in targeting tissue rather than targeting tumor. In addition, not only were the promoters used relatively weak but also only applicable to tumors from a certain origin. Examples are the DF3/MUC1 promoter which was used to direct the expression of Bax to ovarian cancers (Tai et al., 1999) , and the probasin promoter plus androgen response elements which were used to target androgenpositive prostate cancer cells upon induction by androgen (Andriani et al., 2001) . To magnify the application of Bax in cancer therapy, we initiated usage of the hTERT promoter to control Bax gene expression . Using an inducible Gal4 -VP16 system, we have demonstrated that hTERT promoter in adenoviral vector could drive tumor-specific Bax gene expression and induce apoptosis in a variety of human and murine cancer cells but not in normal cells or tissues in vitro and in vivo (Gu et al., , 2002 . However, although we used the binary adenoviral system to successfully demonstrate the concept of using the hTERT promoter for tumor-specific Bax expression and apoptosis, in practical terms, the use of two vectors clinically would raise several concerns, for instance, in co-infection efficiency, and in safety issues. A single adenoviral vector for Bax gene expression is clearly much desirable. However, packaging 293 cells, an immortalized and highly proliferating cell line, have high telomerase activity and hence high hTERT promoter activity. Thus, constructing a straightforward adenoviral vector expressing the Bax gene directly from the hTERT promoter is very difficult if not impossible (our unpublished observation). By modifying the Tet-Off system and by inhibiting Bax expression in 293 cells, we have successfully constructed a novel adenoviral vector, Ad/gBax has several advantages over previously reported Bax-expressing constructs. First, because Ad/ gBax utilizes the hTERT promoter that is active in over 85% of all human cancers, it should be useful for cancers of various origins. Indeed, our data showed that Ad/ gBax induced apoptosis in cancer cells derived from lung, liver, colon, ovary, prostate, and bladder (Figure 2) . Second, Ad/gBax is a single vector that is fully expressible in cancers on its own and does not need an inducer. Moreover, the expression level of GFP-Bax in tumor cells and the resulting apoptosis can be controlled by adding different amounts of Tc. For example, in H1299 cells, as little as 1 ng/ml Tc started to inhibit Bax expression, 5 ng/ml Tc significantly inhibited GFP-Bax expression, and 10 ng/ml Tc inhibited over 80% of Bax expression (Figure 1b) . The inhibition of GFP -Bax expression correlated with the inhibition of apoptosis. In the same experiment (Figure 1b) , the percentage of apoptotic cells induced by Ad/gBax alone or in the presence of various concentration of Tc at 72 h after treatments as determined by FACS were 62.3% (Ad/ gBax alone), 61.7% (0.1 ng/ml Tc), 59.8% (0.5 ng/ml Tc), 49.4% (1 ng/ml Tc), 13.9% (5 ng/ml Tc), 6.44% (10 ng/ml), 6.02% (100 ng/ml Tc) and 5.07% (1 mg/ml Tc). This shows that we can use Ad/gBax to study the correlation of the protein level of the death initiator, the effector, and the end-results (apoptosis). A third advantage of Ad/gBax is that the fusion protein, GFP -Bax, does not change the pro-apoptotic activity of the Bax protein, but gives the vector a reporter property. Using a fluorescence microscope, we could easily detect the infected cells and the relative hTERT promoter strength and the apoptosis induced by Ad/ gBax. Stem cells are capable of self-renewal and have telomerase activity detectable by sensitive assays (Morrison et al., 1996; Yui et al., 1998) . The potential toxic effects to stem cells have become one of the major concerns when using the hTERT promoter to drive proapoptotic or cytotoxic gene expression. However, stem cells are resistant to adenovirus infection. Even with a very high dose of an adenoviral vector and prolonged cell-vector contact, only a limited percentage of stem cells became infected (Watanabe et al., 1996; Feldman et al., 1997; Gu et al., 2002) . In addition, we have shown that the hTERT promoter is much less active in CD34 + hematopoietic progenitor cells which is enriched in stem cells than in cancer cells (Gu et al., 2002) . This is consistent with another report that normal human myeloid progenitor cells (CD34 + CD33 7 ) had barely detectable telomerase activity while leukemia cells had high telomerase activity (Zhang et al., 1996) . The difference in hTERT promoter activities between tumor cells and progenitor stem cells could therefore provide a 'window' that allows the use of pro-apoptotic genes for cancer treatment without causing significant toxicity to stem cells. Furthermore, if the hTERT promoter is used in the context of vectors that transduce stem cells poorly, such as adenovirus, the toxicity of hTERT promoter-mediated pro-apoptotic gene expression in stem cells would be minimal.
In conclusion, we successfully constructed a single tetracycline-regulative adenoviral vector for tumorspecific Bax gene expression and cell killing. Our in vitro and in vivo data suggests that Ad/gBax may become a potent therapeutic agent for the treatment of cancers. In addition, there have been reports that overexpression of Bax enhances chemotherapy and radiation therapy and improves the clinical outcome (Sakakura et al., 1997; Tai et al., 1998; Xiang et al., 2000) . Whether Ad/gBax can be used as a radiosensitizer and/or chemo-sensitizer in cancer therapy warrants further studies.
Materials and methods
Construction of recombinant adenovirus vectors
Vectors Ad/GT -Bax and Ad/hTERT -GV16 were constructed as described previously . Ad/ CMV -GFP was provided by Dr TJ Liu of our institution. Ad/gBax was constructed using a previously described method . Briefly, an adenoviral shuttle vector (pAd/hTERT -gBax) was constructed that contained two expression cassettes, one for the GFP -Bax fusion, whose gene is driven by a synthetic minimal promoter composed of tetracycline-responsive elements (TRE) and CMV minipromoter, and the other for rTA, a transactivator whose gene is driven by the hTERT promoter. This shuttle plasmid was then cotransfected into 293 cells along with a 35-kb ClaI fragment from adenovirus type 5 in the presence of 10 mg/ml tetracycline (Tc). Recombinant vector Ad/gBax was generated by homologous recombination and plaque-purified. The expansion, purification, titration, and quality analysis of all vectors used were done at the vector core facility of our institution. The titer and yield for Ad/gBax were in the range seen for other E1-deleted adenoviral vectors when amplified in the presence of tetracycline. Virus titers were determined by optical absorbance at A 260 (OD 260 , one A 260 unit=10 12 particles/ml) and by plaque assay. Titers determined by OD 260 (i.e. viral particles) were used in all the experiments. Particle/plaque ratios normally fell between 30 : 1 and 100 : 1. All viral preparations were free of contamination by E1 + adenovirus and endotoxin.
Cell lines and in vitro gene transfer
Human lung cancer cell lines H1299, A549, H358, and H322, hepatoma cancer cell line HepG2, cervix cancer cell line Siha, ovarian cancer cell line OVCAR3, prostate cancer cell line DU145, bladder cell line HTB9 and osteosarcoma cell line Saos-2 were originally obtained from the American Type Culture Collection (ATCC) and maintained in our laboratory in medium as suggested by ATCC. Colon cancer cell line Lovo was obtained from Dr T Fujiwara (Okayama University, Japan). Normal human lung fibroblast (NHFB) cells were purchased from Clonetics (San Diego, CA, USA) and cultured in medium recommended by the manufacturer. The optimal MOI, at which over 80% of the cells were infected by reporter virus as determined by pilot experiments, for these cell lines were: 2000 viral particles/cell for H1299, H358, Lovo and HepG2 cells and 3000 viral particles/cell for A549, H322, DU145, OVCAR, HTB9 and NHFB cells. For fluorescence and cell morphology experiments, cells were plated onto 60 mm dishes at a density of 2610 5 /dish and treated with viruses and 48 h later, pictures were taken with a fluorescence microscope for GFP expression or a Nikon digital camera for cell morphology. For XTT assay, cells were plated onto 96-well plates at a density of 5610 3 per well 1 day prior to virus infection. Cell viability was determined 24, 48 and 72 h after infection by a colorimetric assay with a tetrazolium dye XTT using Cell Proliferation Kit II (Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer's protocol. These experiments were performed at least twice for each cell line.
Flow cytometry
Cells were plated at densities of 1610 6 /100 mm and infected with different recombinant adenoviral vectors. Seventy-two hours later, both adherent and floating cells were harvested by trypsinization, washed with phosphate-buffered saline (PBS), and fixed in 70% ethanol overnight. Cells were then stained with propidium iodide for the analysis of DNA content. Apoptotic cells were quantified by flow cytometry performed in the Flow Cytometry Core Laboratory at our institution.
Animal experiments
All mice were cared for according to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication number 85-23) and the institutional guidelines of The University of Texas M.D. Anderson Cancer Center. The in vivo infusion of adenoviral vectors into and subsequent tissue removal from BALB/c mice were done as described previously . In the subcutaneous tumor model, 5610 6 H1299 cells were inoculated subcutaneously into the dorsal flank of 6-to 8-week-old nude mice (Harlan-Sprague Dawley, Indianapolis, IN, USA) to establish tumors. After tumors reached *5 mm in diameter, mice were given three sequential intratumoral injections of 9610 10 viral particles in a volume of 100 ml per dose. Tumors were measured three times a week. Tumor volumes were calculated using the formula a6b 2 60.5, where a and b represent the larger and smaller diameters, respectively.
TUNEL staining
The tumors were resected from mice 48 h after intratumoral injection. Apoptosis in the tumors was assessed by in situ TUNEL staining as we have reported previously (Kawaga et al., 2000) . Briefly, the paraffin-embedded sections were deparaffinized and rehydrated. The slides were incubated in 3% H 2 O 2 /methanol for 10 min at room temperature and then with 0.02% protease/PBS for 30 min at 378C. After incubating the slides with reaction buffer containing terminal deoxyrobonucleotidyl transferase (TdT) according to the manufacturer's protocol (Roche Molecular Biochemicals, Indianapolis, IN, USA), the slides were stained using a Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA) and counter stained with 4% methyl green.
Statistical analysis
Differences among the treatment groups were assessed by analysis of variance (ANOVA) using a statistical software (StatSoft, Tulsa, OK, USA). For the studies of tumor growth in vivo, ANOVA with a repeated measurement model was used. P50.05 was considered significant. Abbreviations TRAIL, TNF-related apoptosis-inducing ligand; GFP, green fluorescent protein; GT, Gal4/TATA; GV16, Gal4-VP16 fusion protein; PGK, 3-phosphoglycerate kinase; PARP, poly(ADP-ribose) polymerase; XTT, 2,3-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanilide; TUNEL, TdT-mediated dUTP-biotin nick-end labeling; FACS, fluorescence-activated cell sorting; MOI, multiplicity/multiplicities of infection.
